Cargando…
SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phospha...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927946/ https://www.ncbi.nlm.nih.gov/pubmed/36626230 http://dx.doi.org/10.1172/JCI162870 |
_version_ | 1784888549855723520 |
---|---|
author | Li, Yiqing Zhou, Hui Liu, Pan Lv, Dandan Shi, Yichun Tang, Bufu Xu, Jiaqi Zhong, Tingting Xu, Wangting Zhang, Jie Zhou, Jianying Ying, Kejing Zhao, Yongchao Sun, Yi Jiang, Zhinong Cheng, Hongqiang Zhang, Xue Ke, Yuehai |
author_facet | Li, Yiqing Zhou, Hui Liu, Pan Lv, Dandan Shi, Yichun Tang, Bufu Xu, Jiaqi Zhong, Tingting Xu, Wangting Zhang, Jie Zhou, Jianying Ying, Kejing Zhao, Yongchao Sun, Yi Jiang, Zhinong Cheng, Hongqiang Zhang, Xue Ke, Yuehai |
author_sort | Li, Yiqing |
collection | PubMed |
description | SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phosphatase SHP2. Mechanistically, Src homology region 2–containing protein tyrosine phosphatase 2 (SHP2) was constitutively neddylated on K358 and K364 sites; thus, its autoinhibited conformation was maintained. In response to CD47-liganded SIRPα, SHP2 was deneddylated by sentrin-specific protease 8 (SENP8), which led to the dephosphorylation of relevant substrates at the phagocytic cup and subsequent inhibition of macrophage phagocytosis. Furthermore, neddylation inactivated myeloid-SHP2 and greatly boosted the efficacy of colorectal cancer (CRC) immunotherapy. Importantly, we observed that supplementation with SHP2 allosteric inhibitors sensitized immune treatment–resistant CRC to immunotherapy. Our results emphasize that the CRC subtype that is unresponsive to immunotherapy relies on SIRPα(hi)SHP2(hi)NEDD8(lo) TIMs and highlight the need to further explore the strategy of SHP2 targeting in CRC therapy. |
format | Online Article Text |
id | pubmed-9927946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-99279462023-02-15 SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis Li, Yiqing Zhou, Hui Liu, Pan Lv, Dandan Shi, Yichun Tang, Bufu Xu, Jiaqi Zhong, Tingting Xu, Wangting Zhang, Jie Zhou, Jianying Ying, Kejing Zhao, Yongchao Sun, Yi Jiang, Zhinong Cheng, Hongqiang Zhang, Xue Ke, Yuehai J Clin Invest Research Article SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phosphatase SHP2. Mechanistically, Src homology region 2–containing protein tyrosine phosphatase 2 (SHP2) was constitutively neddylated on K358 and K364 sites; thus, its autoinhibited conformation was maintained. In response to CD47-liganded SIRPα, SHP2 was deneddylated by sentrin-specific protease 8 (SENP8), which led to the dephosphorylation of relevant substrates at the phagocytic cup and subsequent inhibition of macrophage phagocytosis. Furthermore, neddylation inactivated myeloid-SHP2 and greatly boosted the efficacy of colorectal cancer (CRC) immunotherapy. Importantly, we observed that supplementation with SHP2 allosteric inhibitors sensitized immune treatment–resistant CRC to immunotherapy. Our results emphasize that the CRC subtype that is unresponsive to immunotherapy relies on SIRPα(hi)SHP2(hi)NEDD8(lo) TIMs and highlight the need to further explore the strategy of SHP2 targeting in CRC therapy. American Society for Clinical Investigation 2023-02-15 /pmc/articles/PMC9927946/ /pubmed/36626230 http://dx.doi.org/10.1172/JCI162870 Text en © 2023 Li et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Li, Yiqing Zhou, Hui Liu, Pan Lv, Dandan Shi, Yichun Tang, Bufu Xu, Jiaqi Zhong, Tingting Xu, Wangting Zhang, Jie Zhou, Jianying Ying, Kejing Zhao, Yongchao Sun, Yi Jiang, Zhinong Cheng, Hongqiang Zhang, Xue Ke, Yuehai SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis |
title | SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis |
title_full | SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis |
title_fullStr | SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis |
title_full_unstemmed | SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis |
title_short | SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis |
title_sort | shp2 deneddylation mediates tumor immunosuppression in colon cancer via the cd47/sirpα axis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927946/ https://www.ncbi.nlm.nih.gov/pubmed/36626230 http://dx.doi.org/10.1172/JCI162870 |
work_keys_str_mv | AT liyiqing shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT zhouhui shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT liupan shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT lvdandan shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT shiyichun shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT tangbufu shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT xujiaqi shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT zhongtingting shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT xuwangting shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT zhangjie shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT zhoujianying shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT yingkejing shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT zhaoyongchao shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT sunyi shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT jiangzhinong shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT chenghongqiang shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT zhangxue shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis AT keyuehai shp2deneddylationmediatestumorimmunosuppressionincoloncancerviathecd47sirpaaxis |